World's Best Scientists 2026 revealed!
Alexander M. Menzies

Alexander M. Menzies

D-Index & Metrics

Medicine

D-Index
88
Citations
34047
World Ranking
13015
National Ranking
425

Overview

Alexander M. Menzies is affiliated with the University of Sydney in Australia. Their research primarily focuses on medicine with a strong emphasis on oncology, evidenced by 467 publications in this subfield.

Their work extends to related areas such as molecular biology, immunology, pulmonary and respiratory medicine, and epidemiology. The subfield publication counts are 122 for molecular biology, 97 for immunology, 30 for pulmonary and respiratory medicine, and 19 for epidemiology.

Menzies has contributed extensively to topics including cancer immunotherapy and biomarkers, with 384 publications. Other significant topics in their research portfolio include CAR-T cell therapy research (226 publications), cutaneous melanoma detection and management (212 publications), melanoma and MAPK pathways (184 publications), immunotherapy and immune responses (156 publications), brain metastases and treatment (40 publications), and cancer genomics and diagnostics (34 publications).

Frequent coauthors collaborating with Menzies include:

  • Georgina V. Long (250 joint publications)
  • Matteo S. Carlino (129 joint publications)
  • Richard A. Scolyer (128 joint publications)
  • Serigne Lo (92 joint publications)
  • Robyn P.M. Saw (76 joint publications)

Scholarly output by Menzies appears prominently in several leading journals. The most frequent publication venues are:

  • Journal of Clinical Oncology (62 publications)
  • Annals of Oncology (35 publications)
  • European Journal of Cancer (32 publications)
  • Cancer Research (18 publications)
  • Journal for ImmunoTherapy of Cancer (16 publications)

Recent representative publications by Menzies and collaborators include:

  • Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC), 2021, Nature Medicine
  • Cutaneous melanoma, 2023, The Lancet
  • Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma, 2021, Nature Medicine
  • Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial, 2022, Nature Medicine
  • Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition, 2020, Nature Communications

Best Publications

  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

  • Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

    Georgina V. Long;Alexander M. Menzies;Adnan M. Nagrial;Lauren E. Haydu

  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz

  • Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

    Georgina V Long;Victoria Atkinson;Serigne Lo;Shahneen Sandhu

  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

    Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson

  • Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

    Tuba N. Gide;Camelia Quek;Alexander M. Menzies;Annie T. Tasker

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

  • BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact.

    Helen Rizos;Alexander M. Menzies;Gulietta M. Pupo;Matteo S. Carlino

  • Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

    Alexander M. Menzies;Lauren E. Haydu;Lydia Visintin;Lydia Visintin;Lydia Visintin;Matteo S. Carlino;Matteo S. Carlino

  • PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

    Jason Madore;Ricardo E. Vilain;Ricardo E. Vilain;Alexander M. Menzies;Hojabr Kakavand

  • Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

    Elisa A Rozeman;Alexander M Menzies;Alexander C J van Akkooi;Chandra Adhikari

  • CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

    Jarem Edwards;James S. Wilmott;Jason Madore;Tuba Nur Gide

  • Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

    Celeste Lebbé;Nicolas Meyer;Laurent Mortier;Ivan Marquez-Rodas

  • sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

    Amanpreet Kaur;Amanpreet Kaur;Marie R. Webster;Katie Marchbank;Reeti Behera

  • Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

    Georgina V. Long;Carina Fung;Alexander M. Menzies;Gulietta M. Pupo

  • Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

    M.H. Pollack;M.H. Pollack;A. Betof;H. Dearden;K. Rapazzo;K. Rapazzo

  • Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

    Douglas B. Johnson;Alexander M. Menzies;Lisa Zimmer;Zeynep Eroglu

  • Immune checkpoint inhibitors in challenging populations

    Douglas B. Johnson;Ryan J. Sullivan;Alexander M. Menzies

  • Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

    Alexander M. Menzies;Alexander M. Menzies;Rodabe N. Amaria;Elisa A. Rozeman;Alexander C. Huang

Frequent Co-Authors

Georgina V. Long
Georgina V. Long University of Sydney
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Richard F. Kefford
Richard F. Kefford Macquarie University
John F. Thompson
John F. Thompson University of Sydney
Douglas B. Johnson
Douglas B. Johnson Vanderbilt University Medical Center
Helen Rizos
Helen Rizos Macquarie University
James S. Wilmott
James S. Wilmott University of Sydney
Christian U. Blank
Christian U. Blank Antoni van Leeuwenhoek Hospital
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean traditional medical school. There are diverse online nursing and healthcare degrees that can offer flexible, affordable, and rewarding career pathways.

For those aiming to advance in nursing, phd nursing programs online offer new avenues for leadership, research, and education. If you are a registered nurse seeking to boost your qualifications, choosing from the cheapest online rn to bsn programs can help you progress your career without heavy student debt.

Not from a nursing background? Consider online direct entry msn programs for non-nursing majors. These programs let non-nurses transition to advanced nursing roles in less time through flexible online learning.

If gaining admission is your concern, exploring the easiest nursing schools to get into can help identify more accessible entry points for a fulfilling career in healthcare.

Best Scientists Citing Alexander M. Menzies

Trending Scientists